Phase 3 trials show orforglipron, an oral once-daily GLP-1 receptor agonist, delivers clinically meaningful HbA1c and weight reductioncomparable to injectable GLP-1s
Some options are vitamin or nutrient injections, while others, such as Toradol, Zofran, Semaglutide, and Tirzepatide, require appropriate medical review
Strategic Portfolio Integration When deciding whether to add tirzepatide to development projects, procurement managers and business development workers should think about a number of things
Ipamorelin has limited long-term safety databases but generally appears well-tolerated in small studies
As with any medication, individual responses vary, and those with specific contraindications should not use it
Market Segmentation Analysis Product Type Insights Which Product Type Segment Dominated the GLP-1 Market